What is the appropriate dosing regimen of retatrutide for weight loss in an adult patient with obesity (BMI ≥ 30 kg/m²) without contraindications?

Retatrutide Dosing for Weight Loss

Start retatrutide at 2 mg subcutaneously once weekly, then escalate monthly to a target maintenance dose of 12 mg weekly for maximum weight loss efficacy in adults with obesity.

Dosing Algorithm

Initial Dosing

• Starting dose: 2 mg subcutaneously once weekly 1, 2
• This lower starting dose (2 mg vs. 4 mg) significantly reduces gastrointestinal side effects while maintaining efficacy 2

Dose Escalation Schedule

Escalate monthly based on tolerability:

• Week 1-4: 2 mg weekly
• Week 5-8: 4 mg weekly
• Week 9-12: 8 mg weekly
• Week 13+: 12 mg weekly (target maintenance dose)

Target Maintenance Doses

The evidence demonstrates clear dose-dependent weight loss 1, 2:

• 12 mg weekly: Most effective dose

  • 24.2% weight loss at 48 weeks in obesity without diabetes 2
  • 18.8% weight loss at 80 weeks in obesity with type 2 diabetes 1
  • 100% of patients achieved ≥5% weight loss, 93% achieved ≥10%, and 83% achieved ≥15% 2

• 8 mg weekly: Highly effective alternative

  • 22.8% weight loss at 48 weeks 2
  • 100% achieved ≥5% weight loss, 91% achieved ≥10%, 75% achieved ≥15% 2

• 4 mg weekly: Moderate efficacy option

  • 17.1% weight loss at 48 weeks 2
  • 92% achieved ≥5% weight loss, 75% achieved ≥10%, 60% achieved ≥15% 2

Clinical Context

Retatrutide is a triple-hormone receptor agonist (GIP/GLP-1/glucagon) that produces substantially greater weight loss than currently available GLP-1 receptor agonists 1, 2. The phase 2 and phase 3 trial data show it achieves weight reductions exceeding semaglutide 2.4 mg (13.9% at 68 weeks) and tirzepatide 15 mg (22.5% at 72 weeks) 3, 4.

Important Considerations for Patients with Type 2 Diabetes

Weight loss efficacy is somewhat attenuated in patients with type 2 diabetes compared to those with obesity alone, but remains clinically significant 1. In the TRIUMPH-2 trial of patients with obesity and type 2 diabetes:

• Mean weight loss: 18.8% with 12 mg dose at 80 weeks
• HbA1c reduction: Substantial glycemic improvements observed
• 92% of patients were on oral glucose-lowering medications at baseline 1

Mitigating Gastrointestinal Side Effects

The most critical pitfall is rapid dose escalation, which dramatically increases gastrointestinal adverse events 2.

Key Strategies:

• Always start at 2 mg weekly (not 4 mg) - this reduces nausea, vomiting, and diarrhea while maintaining treatment adherence 2
• Escalate monthly, not more frequently
• Gastrointestinal effects are dose-related, mostly mild-to-moderate, and typically occur during dose escalation 1, 2
• Most common adverse events: diarrhea (27-34% vs. 13% placebo), nausea (14-28% vs. 8% placebo) 1

Monitoring Considerations:

• Heart rate: Dose-dependent increases peak at 24 weeks then decline 2
• Hypotension: More frequent with higher doses (6% with 12 mg vs. <1% placebo) 1
• Dysesthesia: Occurs in 7% with 12 mg dose vs. 1% placebo 1
• Treatment discontinuation due to adverse events: 8-12% with higher doses (9-12 mg) vs. 4-5% with lower doses 1

Treatment Duration

Efficacy data extends to 80 weeks of continuous treatment, with sustained weight loss throughout this period 1. The weight loss trajectory shows continued improvement beyond 48 weeks, suggesting longer treatment durations may be beneficial for maximizing outcomes.